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Figure S1. Analysis of reduced DTPA-hC3a[1-77] 7. A. Analytical HPLC of pure 7. 
Conditions: 0 to 70% buffer B in 20 min. B. Mass spectrum of pure 7: found 9469.0, observed 
mass: 9471.1 Da. 
 
 
Figure S2. Analysis of oxidized DTPA-hC3a[1-77] 8. A. Analytical HPLC of pure 8. 
Conditions: 0 to 60% buffer B in 20 min. B. Mass spectrum of pure 8: found 9463.0, observed 
mass: 9464.8 Da. 
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Figure S3. Competitive binding of Eu-DTPA-hC3a with hC3a on primary human peripheral 
blood mononuclear cells (PBMC). Competitive binding experiments were performed on 
primary human PBMC and Eu-DTPA-C3a (2 nM) in the presence of increasing concentrations 
of human C3a. PBMC were incubated with Eu-DTPA-C3a and hC3a for 60 min at room 
temperature with shaking. Each plot represent one individual donor and error bars represent 
mean ± SEM. 
 
 
Figure S4. Chemical structure of C3aR-specific ligands (TR16, BR103, BR111 and 
SB290157) and C5aR-specific ligand (3D53). 
 
 


















PBMC - Donor 2
IC50 2.7 nM



















PBMC - Donor 1
IC50 1.8 nM
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Table S1. Amino acid sequence and MS analysis of peptide fragments, intermediates and full-
length human C3a. 
Peptide Sequence Found mass by ESI-MS 
Expected 
mass 
1 DTPA-SVQLTEKRMDKVGKYPKELRKC-CONHNH2 3025.2 3026.5 
3 CKKVFLDCCNYITELRRQHARASHLGLAR-COOH 3403.2 3403.0 
4 Thz-EDGMRENPMRFSCQRRTRFISLGEA-COSCH2CH2-CO-Arg 3347.1 3346.8 
5 DTPA-SVQLTEKRMDKVGKYPKELRKC-COSCH2CH2SO3H 3136.8 3136.7 










RTRFISLGEACKKVFLDCCNYITELRRQHARASHLGLAR-COOH (oxid) 9615.5 9614.9 
 
 
Figure S5. HPLC and ESI-MS analytical data of hC3a[1-22]-NHNH2 1 (A) and C3a[1-22]-
COSCH2CH2SO3H 5 (B) peptides. Conditions for analytical HPLC: 5 to 100% B in 10 min 
(A); 0 to 40%B in 20 min (B). 
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temp 1614 (29.607) Cm (1596:1652) TOF MS ES+ 
98757.2606.1
505.4 1008.8
temp 1516 (27.809) Cm (1499:1556) TOF MS ES+ 
223588.7
490.8 735.7
temp 1423 (26.103) Cm (1415:1464) TOF MS ES+ 
155616.6524.2
416.1 770.5










temp 578 (10.602) Cm (571:617) TOF MS ES+ 
57524.1
487.9416.2 606.3569.0 757.5
temp 491 (9.006) Cm (491:536) TOF MS ES+ 
63757.5606.1
502.3 1009.3
temp 336 (6.163) Cm (302:355) TOF MS ES+ 
70606.1
491.8452.6 757.2 1027.9
temp 168 (3.081) Cm (152:193) TOF MS ES+ 
131606.1
364.3 505.5 757.4 1028.4
Analytical HPLC of 
1
ESI-MS of 1
Analytical HPLC 
5
ESI-MS of 5
